Why is Akeso stock plunging today?
On Monday, Akeso stock experienced a steep 22.7% decline, dropping to HK$63.65 following the U.S. FDA's rejection of the company's Biologics License Application for lung cancer treatment ivonescimab. The regulatory body concluded that the treatment lacked significant evidence of efficacy in improving overall survival, severely impacting Akeso's plans to disrupt established immunotherapy standards in the U.S. market.
The stock opened sharply lower, briefly touching a 52-week low of HK$56.1 before showing signs of recovery. Akeso's CEO and co-founder, Dr. Yu (Michelle) Xia, deemed the FDA's decision as the most challenging period in the company's 14-year history, attributing it to enrollment timing differences between Chinese and overseas patients, as well as the struggle to establish effective clinical sites overseas where ivonescimab had limited prior clinical exposure.
The FDA's rejection had a ripple effect across the Hong Kong pharmaceutical sector, causing other biotech stocks to decline, while the broader Hang Seng Index also plummeted due to losses suffered by technology companies.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.